Immunophenotypic Characterization and Quantification of Neoplastic Bone Marrow Plasma Cells by Multiparametric Flow Cytometry and Its Clinical Significance in Korean Myeloma Patients.
10.3346/jkms.2013.28.4.542
- Author:
Young Uk CHO
1
;
Chan Jeoung PARK
;
Seo Jin PARK
;
Hyun Sook CHI
;
Seongsoo JANG
;
Sang Hyuk PARK
;
Eul Ju SEO
;
Dok Hyun YOON
;
Jung Hee LEE
;
Cheolwon SUH
Author Information
1. Department of Laboratory Medicine, University of Ulsan, College of Medicine and Asan Medical Center, Seoul, Korea. cjpark@amc.seoul.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Multiple Myeloma;
Flow Cytometry;
Immunophenotyping;
Neoplastic Cells;
Plasma Cells
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Antigens, CD27/metabolism;
Antigens, CD56/metabolism;
Asian Continental Ancestry Group;
Bone Marrow Cells/*cytology/metabolism;
Female;
Flow Cytometry;
Humans;
*Immunophenotyping;
Kaplan-Meier Estimate;
Male;
Middle Aged;
Multiple Myeloma/metabolism/mortality/*pathology;
Neoplasm Staging;
Neoplastic Stem Cells/*cytology/metabolism;
Prognosis;
Republic of Korea;
Risk Factors
- From:Journal of Korean Medical Science
2013;28(4):542-549
- CountryRepublic of Korea
- Language:English
-
Abstract:
Multiparametric flow cytometry (MFC) allows discrimination between normal and neoplastic plasma cells (NeoPCs) within the bone marrow plasma cell (BMPC) compartment. This study sought to characterize immunophenotypes and quantitate the proportion of NeoPCs in BMPCs to diagnose plasma cell myeoma (PCM) and evaluate the prognostic impact of this method. We analyzed the MFC data of the bone marrow aspirates of 76 patients with PCM and 33 patients with reactive plasmacytosis. MFC analysis was performed using three combinations: CD38/CD138/-/CD45; CD56/CD20/CD138/CD19; and CD27/CD28/CD138/CD117. The plasma cells of patients with reactive plasmacytosis demonstrated normal immunophenotypic patterns. Aberrant marker expression was observed in NeoPCs, with negative CD19 expression observed in 100% of cases, CD56+ in 73.7%, CD117+ in 15.2%, CD27- in 10.5%, CD20+ in 9.2%, and CD28+ in 1.3%. In PCM patients, more than 20% of NeoPCs/BMPCs were significantly associated with factors suggestive of poor clinical outcomes. Patients who were CD27- or CD56+/CD27-, demonstrated shorter overall survival than patients of other CD56/CD27 combinations. Our results support the clinical value of immunophenotyping and quantifying NeoPCs in PCM patients. This strategy could help to reveal poor prognostic categories and delineate surrogate markers for risk stratification in PCM patients.
